A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

Phase 1

Completed

• Conditions: Parkinson Disease; Huntington Disease; Fragile X Syndrome; Alzheimer Disease; Autistic Spectrum Disorders; Mild Cognitive Impairment
• Interventions: Drug: [18F]FPEB

• Registration Number: NCT00870974
• Lead Sponsor: Institute for Neurodegenerative Disorders

Brief Summary

Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).

The goal of this study is to assess \[18F\]F-PEB positron emission tomography (PET) imaging as a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research participants and similarly aged healthy subjects.

Detailed Description

Informed consent will be obtained for all subjects. All subjects will undergo a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. All subjects will undergo \[18F\]F-PEB PET imaging. Subjects may also be asked to undergo standard brain MRI to assist in the analysis of the PET images obtained.

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-03-26
• Study First Submitted QC: 2009-03-26
• Study First Posted: 2009-03-27
• Primary Completion: 2016-10
• Study Completion: 2016-11
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-05
• Last Update Posted: 2017-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Assess [18F]FPEB and PET imaging	[18F]FPEB	To assess \[18F\] FPEB and PET imaging in subjects with neuropsychiatric conditions.

Primary Outcome Measures

Name	Time	Method
Does FPEB reliably represent the known distribution of MGLUR5 in the brain?	at completion of scans

Trial Locations

Locations (1)

Institute for Neurodegenerative Disorders; 🇺🇸 New Haven, Connecticut, United States